Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
ESAIY
)
10.84
+0.06 (+0.51%)
Streaming Delayed Price
Updated: 3:47 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ESAIY
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
April 24, 2024
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares?
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
April 11, 2024
Wall Street often ignores the stocks of companies with huge potential. Here are three overlooked stocks to buy.
Via
InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
February 12, 2024
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks.
Via
InvestorPlace
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...
Via
Talk Markets
Current Analysis: Eisai Co Ltd (ESAIY)
July 16, 2023
Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price.
Via
Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
January 23, 2024
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Via
InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
3 Aging Population Stocks to Profit from the Boomer Generation
December 21, 2023
The elderly population of the U.S. is expected to grow tremendously in the coming years. Here are three stocks to buy for an aging population.
Via
InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Via
Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
November 06, 2023
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
The 3 Best Biotech Stocks to Buy Now: September 2023
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
July 30, 2023
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.
Via
InvestorPlace
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
July 24, 2023
Analysts expect Biogen to report a a decline in both profits and sales in Q2.
Via
Investor's Business Daily
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
July 07, 2023
Via
Benzinga
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
July 06, 2023
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug.
Via
Investor's Business Daily
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
June 09, 2023
A panel of experts will debate the merits of Biogen's drug, Leqembi.
Via
Investor's Business Daily
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
June 07, 2023
The FDA's advisors will consider the full approval of Leqembi on Friday.
Via
Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
June 01, 2023
The news also benefits Biogen's partner Eisai and rival Eli Lilly.
Via
Investor's Business Daily
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
May 15, 2023
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market.
Via
Investor's Business Daily
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
May 11, 2023
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.
Via
Investor's Business Daily
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
April 25, 2023
The company is hopeful for maintenance dosing and a new injection of the drug.
Via
Investor's Business Daily
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
April 16, 2023
Biotech stocks are highly speculative, but it's possible to choose ones with excellent risk-reward ratios.
Via
InvestorPlace
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
April 07, 2023
These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire.
Via
InvestorPlace
7 A-Rated Stocks to Buy for April 2023
April 07, 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape.
Via
InvestorPlace
7 Core Stocks to Build a Solid Portfolio Around
March 13, 2023
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.
Via
InvestorPlace
7 Smart Stock Picks for Cautious Investors
February 28, 2023
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors.
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.